Additional file 1: of Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

Reichardt, Peter; Demetri, George; Gelderblom, Hans; Rutkowski, Piotr; Im, Seock-Ah; Gupta, Sudeep; Kang, Yoon-Koo; SchĂśffski, Patrick; Schuette, Jochen; SouliĂ¨res, Denis; Blay, Jean-Yves; Goldstein, David; Fly, Kolette; Huang, Xin; Corsaro, Massimo; Lechuga, Maria; Martini, Jean-Francois; Heinrich, Michael

doi:10.6084/m9.figshare.c.3609755_D1.v1

12885_2016_2051_MOESM1_ESM.doc (64 kB)

Additional file 1: of Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

journal contribution

posted on 2016-01-15, 05:00 authored by Peter Reichardt, George Demetri, Hans Gelderblom, Piotr Rutkowski, Seock-Ah Im, Sudeep Gupta, Yoon-Koo Kang, Patrick SchĂśffski, Jochen Schuette, Denis SouliĂ¨res, Jean-Yves Blay, David Goldstein, Kolette Fly, Xin Huang, Massimo Corsaro, Maria Lechuga, Jean-Francois Martini, Michael Heinrich

Supplementary Methods and Results. (DOC 64 kb)

Funding

National Cancer Institute (US)

History

Usage metrics

Keywords

Sunitinib Imatinib GIST KIT KIT mutation Imatinib-resistant GIST Overall survival Progression-free survival

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: of Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

Funding

National Cancer Institute (US)

History

Usage metrics

Categories

Keywords

Licence

Exports